autoimmune disease

Pfizer's Unheralded Franchise That's Worth Billions of Dollars
Pfizer's Unheralded Franchise That's Worth Billions of Dollars
Motley Fool
Pfizer
biosimilars
Humira
Inflectra
Remsima
Remicade
autoimmune disease
JNJ
Flag link:
Pandion Raises $80 Million Series B to Advance Autoimmune Therapies
Pandion Raises $80 Million Series B to Advance Autoimmune Therapies
BioSpace
Pandion Therapeutics
autoimmune disease
Flag link:
Lilly pays Sitryx $50M upfront for preclinical autoimmune assets
Lilly pays Sitryx $50M upfront for preclinical autoimmune assets
Fierce Biotech
Eli Lilly
Sitryx
autoimmune disease
Flag link:
Thymus atlas could spark new treatments for cancer, autoimmune disease
Thymus atlas could spark new treatments for cancer, autoimmune disease
Fierce Biotech
thymus
autoimmune disease
cancer
Flag link:
Sonoma Bio Launches With $40M to Take Cell Therapy Beyond Cancer
Sonoma Bio Launches With $40M to Take Cell Therapy Beyond Cancer
Xconomy
Sonoma Biosciences
cell therapy
autoimmune disease
Flag link:
5 years of biosimilars in the US: what have we learned?
5 years of biosimilars in the US: what have we learned?
Pharmaforum
biosimilars
cancer
autoimmune disease
Flag link:
Adrangi mounts short attack on 'worthless' drugs of Sanofi ally
Adrangi mounts short attack on 'worthless' drugs of Sanofi ally
Fierce Biotech
Principia Biopharma
Sanofi
autoimmune disease
Kerrisdale Capital
Flag link:
2 Biotechs Battling Immune Diseases
2 Biotechs Battling Immune Diseases
Motley Fool
Rigel Pharmaceuticals
Momenta Pharmaceuticals
autoimmune disease
biologics
small molecule drugs
Flag link:
After closing one of China's biggest-ever raises, I-Mab Biopharma nabs $104M Nasdaq IPO
After closing one of China's biggest-ever raises, I-Mab Biopharma nabs $104M Nasdaq IPO
Fierce Biotech
IPOs
China
NASDAQ
I-Mab Biopharma
autoimmune disease
cancer
Flag link:
Upcoming events – Wave takes on Huntington's and Argenx goes subcutaneous
Upcoming events – Wave takes on Huntington's and Argenx goes subcutaneous
EP Vantage
Wave Life Sciences
WVE-120101
Huntington's disease
Argenx
efgartigimod
autoimmune disease
Flag link:
J&J's Remicade losing ground in Quebec health plan despite court victory
J&J's Remicade losing ground in Quebec health plan despite court victory
Yahoo/Reuters
JNJ
Canada
Quebec
Remicade
autoimmune disease
Flag link:
Pandion, Astellas sign $900m deal for pancreas-targeted immunomodulators
Pandion, Astellas sign $900m deal for pancreas-targeted immunomodulators
Pharmaceutical Business Review
Astellas
Pandion Therapeutics
immunomodulators
autoimmune disease
Pancreas
Flag link:
CAR-T cells as 'bait' show promise in autoimmune disease
CAR-T cells as 'bait' show promise in autoimmune disease
Fierce Biotech
CAR-T
autoimmune disease
Flag link:
Oxford spinout MiroBio bags £27M for autoimmune R&D
Oxford spinout MiroBio bags £27M for autoimmune R&D
Fierce Biotech
MiroBio
autoimmune disease
R&D
Flag link:
Cabaletta Bio Files for $100 Million IPO
Cabaletta Bio Files for $100 Million IPO
CP Wire
Cabaletta Bio
IPOs
autoimmune disease
DSG3-CAART
pemphigus vulgaris
Flag link:
Promising autoimmune biotech gets $40 million as celiac drug is pushed to clinic
Promising autoimmune biotech gets $40 million as celiac drug is pushed to clinic
Endpoints
celiac disease
autoimmune disease
Anokion
Kanyos Bio
Kan-101
Flag link:
FDA approves Rituxan biosimilar
FDA approves Rituxan biosimilar
Beckers Hospital Review
Pfizer
biosimilars
FDA
Ruxience
cancer
autoimmune disease
Genentech
Flag link:
Alexion's cash cow Soliris just got fatter as FDA greenlights another blockbuster indication
Alexion's cash cow Soliris just got fatter as FDA greenlights another blockbuster indication
Endpoints
Alexion
Soliris
FDA
autoimmune disease
NMOSD
Flag link:
AstraZeneca spinout Viela Bio pockets $75M on its way to BLA for autoimmune drug
AstraZeneca spinout Viela Bio pockets $75M on its way to BLA for autoimmune drug
Endpoints
Viela Bio
AstraZeneca
autoimmune disease
Flag link:
Genentech lines up a new autoimmune R&D alliance on a 'potentially transformative' tech
Genentech lines up a new autoimmune R&D alliance on a 'potentially transformative' tech
Endpoints
Parvus Therapeutics
Genentech
drug discovery
autoimmune disease
Flag link:

Pages